
For decades, doctors have been puzzled by why women develop Alzheimer’s disease at nearly twice the rate of men. Limited time: Save 25% on NBC News subscription Get exclusive reporting, live Q&As and ad-free reading. There are an estimated 7 million people in the U.S. living with Alzheimer’s, with that number expected to reach nearly 13 million by 2050. A majority of cases, or about 2 out of every 3, are in women.
Main Idea: Doctors are studying whether starting hormone therapy during perimenopause could help protect women from dementia later in life, but experts say it is not ready to be used for Alzheimer’s prevention.
Key Points:
Hormone therapy may be prescribed more often before the evidence is clear, which could expose some women to side effects or false hope about dementia prevention.
New research at Weill Cornell Medicine and a looser FDA warning may help doctors find safer menopause treatments and possibly lower dementia risk for some women.
Rate how each entity in this article affected the American people.
Leading Alzheimer’s researcher cited as driving a major research initiative on women’s dementia risk.
Home institution for key researchers and host of the CARE women’s Alzheimer’s-risk initiative.
Central regulator whose removal of the black-box warning is a major driver of the article’s discussion.
Named neurologist quoted on the possible treatment window during perimenopause.
Named physician quoted to explain menopause timing and hormone changes.
Named researcher quoted on estrogen’s role in the brain and Alzheimer’s risk.
Institutional affiliation for a quoted neurology researcher, included as supporting context.
Comments here are the same thread shown when this article appears in The Pulse.
No comments on this article yet.
Sign in to commentInstitutional affiliation for a quoted menopause expert, included as supporting context.
Named professional organization where related research was presented.
Named journal cited as the publication venue for research findings.